Semyonov A V, Zazulin S K, Stefani D V
Moscow Research Institute of Pediatrics and Pediatrics Surgery, Ministry of Health and Medical Industry of the Russian Federation, Moscow.
Immunol Lett. 1995 Jul-Aug;47(1-2):59-62. doi: 10.1016/0165-2478(95)00076-h.
A new highly effective pathogenetic therapy for anaphylactic reaction in vivo has been suggested. Forty-three guinea pigs, presensitized with horse serum and divided into two groups, were injected intracardially with 1 ml of 1.6 x 10(-4) M cytochalasin D and 1 ml of 1.6 x 10(-5) M cytochalasin D in DMSO solution at various times before being challenged with the serum. Experimental data not only showed that anaphylactic reaction can be suppressed in vivo by blocking cytoskeletal activity but also demonstrated different pharmacodynamic characteristics of cytochalasin D on clinical course, gravity and outcome of anaphylactic shock in sensitized guinea pigs, depending on the interval between administration of the drug and allergen.
一种针对体内过敏反应的新型高效致病疗法已被提出。43只预先用马血清致敏并分为两组的豚鼠，在接受血清激发前的不同时间，经心内注射1毫升二甲基亚砜溶液中1.6×10⁻⁴M的细胞松弛素D和1毫升1.6×10⁻⁵M的细胞松弛素D。实验数据不仅表明通过阻断细胞骨架活性可在体内抑制过敏反应，还证明了细胞松弛素D对致敏豚鼠过敏休克的临床病程、严重程度和结局具有不同的药效学特征，这取决于药物与过敏原给药之间的间隔时间。
